Device Trial Radar · NCT00624390
Sepraspray™ Laparoscopic Myomectomy Study
Last checked: Nov 20, 2026Latest source record: Dec 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Nov 2007
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanyNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 27, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compare treatment with Sepraspray as a adhesion prevention barrier after laparoscopic myomectomy versus no adhesion barrier.
Conditions
- Laparoscopic Myomectomy
Interventions
SeprasprayDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety endpoints will include the type and incidence of AEs, vital signs, wound healing, laboratory examinations, and medication usage.Time frame: 30 Days post surgery
- Efficacy endpoints are on adhesion formation and will include the success the success criterion for the individual patients as either anterior or posterior uterus free of dense adhesions.Time frame: Until end of study
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Naperville, Illinois
Site not named
Philadelphia, Pennsylvania
Site not named
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.